‘ready-to-use’ frozen cells. In this presentation, I will introduce the current status of our developments to provide a platform for discussing future therapies for treating corneal endothelial decompensation.

We will analyze why there is not yet an alternative process for mass production of corneal endothelial cells or clinical grade TEEK, systematically detailing the various bottlenecks identified, from the source of cells and media, to regulatory and economic aspects.